Cargando…

Inflammation-Related Signature Profile Expression as a Poor Prognosis Marker after Oxaliplatin Treatment in Colorectal Cancer

Oxaliplatin is successfully used to eradicate micro-metastasis and improve survival, whereas the benefit of adjuvant chemotherapy in the early stages of colorectal cancer remains controversial. Inflammation plays a crucial role in colorectal cancer tumorigenesis. Inflammatory mechanisms are mediated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martinez-Bernabe, Toni, Oliver, Jordi, Sastre-Serra, Jorge, Pons, Daniel Gabriel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965239/ https://www.ncbi.nlm.nih.gov/pubmed/36835258 http://dx.doi.org/10.3390/ijms24043821

Ejemplares similares

Estrogen Receptor Beta (ERβ) Maintains Mitochondrial Network Regulating Invasiveness in an Obesity-Related Inflammation Condition in Breast Cancer
por: Martinez-Bernabe, Toni, et al.
Publicado: (2021)

Use of Omics Technologies for the Detection of Colorectal Cancer Biomarkers
por: Alorda-Clara, Marina, et al.
Publicado: (2022)

Gene signatures associated with drug resistance to irinotecan and oxaliplatin predict a poor prognosis in patients with colorectal cancer
por: Sun, Xinrong, et al.
Publicado: (2017)

High Concentrations of Genistein Decrease Cell Viability Depending on Oxidative Stress and Inflammation in Colon Cancer Cell Lines
por: Alorda-Clara, Marina, et al.
Publicado: (2022)

Sexual hormones regulate the redox status and mitochondrial function in the brain. Pathological implications
por: Torrens-Mas, Margalida, et al.
Publicado: (2020)

Inflammation- and Metastasis-Related Proteins Expression Changes in Early Stages in Tumor and Non-Tumor Adjacent Tissues of Colorectal Cancer Samples
por: Alorda-Clara, Marina, et al.
Publicado: (2022)

Podocalyxin is a marker of poor prognosis in colorectal cancer
por: Kaprio, Tuomas, et al.
Publicado: (2014)

Micronutrients Selenomethionine and Selenocysteine Modulate the Redox Status of MCF-7 Breast Cancer Cells
por: Pons, Daniel Gabriel, et al.
Publicado: (2020)

Association of High LAT1 Expression with Poor Prognosis and Recurrence in Colorectal Cancer Patients Treated with Oxaliplatin-Based Adjuvant Chemotherapy
por: Shibasaki, Yuta, et al.
Publicado: (2023)

Comparison of Colorectal Cancer Stem Cells and Oxaliplatin-Resistant Cells Unveils Functional Similarities
por: Rodríguez-Fanjul, Vanessa, et al.
Publicado: (2022)

An Autophagy-Related Long Noncoding RNA Signature Contributes to Poor Prognosis in Colorectal Cancer
por: Wei, Jingsun, et al.
Publicado: (2020)

Carcinoma-associated fibroblasts affect sensitivity to oxaliplatin and 5FU in colorectal cancer cells
por: Gonçalves-Ribeiro, Samuel, et al.
Publicado: (2016)

p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosis
por: Solé, Laura, et al.
Publicado: (2022)

Construction and Validation of an Oxaliplatin-Resistant Gene Signature in Colorectal Cancer Patients Who Underwent Chemotherapy
por: Yin, Yixin, et al.
Publicado: (2022)

OTUB1 promotes metastasis and serves as a marker of poor prognosis in colorectal cancer
por: Zhou, Yi, et al.
Publicado: (2014)

Role of oxaliplatin in the treatment of colorectal cancer
por: Comella, Pasquale, et al.
Publicado: (2009)

Oxaliplatin-Induced Neuropathy in Colorectal Cancer
por: Weickhardt, Andrew, et al.
Publicado: (2011)

Lack of MMP-9 expression is a marker for poor prognosis in Dukes’ B colorectal cancer
por: Koskensalo, Selja, et al.
Publicado: (2012)

SMAD4 alteration associates with invasive‐front pathological markers and poor prognosis in colorectal cancer
por: Oyanagi, Hidehito, et al.
Publicado: (2019)

Validation of Genetic Markers Associated with Survival in Colorectal Cancer Patients Treated with Oxaliplatin-Based Chemotherapy
por: Park, Hanla A., et al.
Publicado: (2022)

A novel inflammation-related signature for predicting prognosis and characterizing the tumor microenvironment in colorectal cancer
por: Li, Jinna, et al.
Publicado: (2023)

Interleukin-11-expressing fibroblasts have a unique gene signature correlated with poor prognosis of colorectal cancer
por: Nishina, Takashi, et al.
Publicado: (2021)

RYBP contributes to improved prognosis in colorectal cancer via regulation of cell cycle, apoptosis and oxaliplatin sensitivity
por: Morinaka, Takashi, et al.
Publicado: (2023)

Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab
por: Liu, Yingmiao, et al.
Publicado: (2013)

Methylation of DIRAS1 promotes colorectal cancer progression and may serve as a marker for poor prognosis
por: Zheng, Ruipan, et al.
Publicado: (2017)

Oxaliplatin related lncRNAs prognostic models predict the prognosis of patients given oxaliplatin-based chemotherapy
por: Zhou, Qing-nan, et al.
Publicado: (2023)

Adrenomedullin: a marker of impaired hemodynamics, organ dysfunction, and poor prognosis in cardiogenic shock
por: Tolppanen, Heli, et al.
Publicado: (2017)

A Prognosis Marker SLC2A3 Correlates With EMT and Immune Signature in Colorectal Cancer
por: Gao, Huabin, et al.
Publicado: (2021)

Novel Epigenetic Eight-Gene Signature Predictive of Poor Prognosis and MSI-Like Phenotype in Human Metastatic Colorectal Carcinomas
por: Condelli, Valentina, et al.
Publicado: (2021)

RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients
por: Cross-Knorr, Sam, et al.
Publicado: (2013)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial
por: Madi, A, et al.
Publicado: (2012)

Scutellarin resensitizes oxaliplatin-resistant colorectal cancer cells to oxaliplatin treatment through inhibition of PKM2
por: Sun, Wei, et al.
Publicado: (2021)

Tumour markers of prognosis in colorectal cancer
por: McLeod, H L, et al.
Publicado: (1999)

Smoking is an Independent Marker of Poor Prognosis in Cutaneous Melanoma
por: MATTILA, Kalle, et al.
Publicado: (2023)

Intestinal obstruction: predictor of poor prognosis in colorectal carcinoma?
por: Mohd Suan, Mohd Azri, et al.
Publicado: (2015)

STAT1 as a potential prognosis marker for poor outcomes of early stage colorectal cancer with microsatellite instability
por: Tanaka, Atsushi, et al.
Publicado: (2020)

SIRT3: Oncogene and Tumor Suppressor in Cancer
por: Torrens-Mas, Margalida, et al.
Publicado: (2017)

Sarcoidosis Associated with Oxaliplatin-Based Chemotherapy for Colorectal Cancer
por: Choi, Ji Hoon, et al.
Publicado: (2014)

Synergistic effect of sodium butyrate and oxaliplatin on colorectal cancer
por: Shuwen, Han, et al.
Publicado: (2022)

Gemcitabine: An Alternative Treatment for Oxaliplatin-Resistant Colorectal Cancer
por: Chocry, Mathieu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_na5ei34li49md0gsu1dmu2mq0u